Komori
Financial results presentation4883Modalis Therapeutics CorporationPharmaceuticals

(Correction) Notice Regarding Corrections to the Second-Quarter Financial Results Presentation for the Fiscal Year Ending December 2026

The income statement on page 27 of the earnings presentation materials for the second quarter of the fiscal year ending December 2026 was corrected, along with minor typographical errors and omissions. There is no impact on the figures in the earnings summary or on financial performance.

Worth reading
38Recurring
Scored from 2 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure10 August 2026

Financial Results Briefing Materials for the Second Quarter of the Fiscal Year Ending December 2026

Open the original document
Corrected on the same dayCorrected on the same day as the original document (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2026-08-10
Location of correction (where in the original document)

p.27 Financial position at the end of the second quarter of 2026 (income statement)

Impact on Business Performance (the company’s explanation)

There is no impact on the figures in the earnings summary for the second quarter of the fiscal year ending December 2026 or on financial performance.

Reason for correction

Because certain information was incorrectly stated. Minor typographical errors and omissions were also corrected.

What was corrected and how
ItemDetails
Disclosure subject to correctionFinancial Results Briefing Materials for the Second Quarter of the Fiscal Year Ending December 2026
Original disclosure date10 August 2026
Location of correctionp.27 Financial position at the end of the second quarter of 2026 (income statement)
Reason for correctionBecause certain information was incorrectly stated. Minor typographical errors and omissions were also corrected.
Impact on Business PerformanceThere is no impact on the figures in the earnings summary for the second quarter of the fiscal year ending December 2026 or on financial performance.
Items this document does not state (1)
Details of correction

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because certain information in the earnings presentation materials was incorrectly stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Notice Regarding Corrections to the Second-Quarter Financial Results Presentation for the Fiscal Year Ending December 2026 | Modalis Therapeutics Corporation (4883) timely disclosure | Komori